Download het volledig rapport (302 p.) - KCE

KCE reports vol. 6A Prenatale zorg 133
Study Ref Population Intervention Outcomes Results Comments Study
type
no zidovudine Other delivery mode + no
zidovudine: 55/271 infected
(20%, 95% CI 16% to 24%)
Shey Wiysonge
et al., 2002
Duong et al.,
1999
4
[618]
4
[411]
2 RCTs, 1813 known
HIV infected women
who are pregnant
Cochrane review
Most recent update 2002
Pregnant women with
HIV infection reported
through obstetric
surveillance in the British
Isles
Vitamin A
supplementation
during pregnancy vs.
placebo or
micronutrient
supplementation
Surveillance of
mother-to-child
transmission of HIV
infection
HIV infection status of
child
Mother-to-child
transmission rate by
infection status of child
among women who
did not breastfeed
Reduction of risk of
Risk difference for
zidovudine:
8 (95% CI 14 to 2) for
caesarean section
3 (95% CI 19 to 12)
for other delivery modes
Risk difference for
caesarean section:
17 (95% CI 32 to 2)
for zidovudine
12 (95% CI 20 to 5)
for no zidovudine
OR 1.09 (95% CI 0.81 to
1.45)
Mother-to-child
transmission rate by
infection status of child
among women who did not
breastfeed: 19.6% (8.0% to
32%) in 1993; 2.2% (0% to
7.8%) in 1998
Both studies are described
as randomised and double
blind, although one study did
not report the method of
allocation concealment. In
one study, 7.8% of women
were excluded from the
analysis and 5% were lost to
follow-up in the other
EL
SR 1a